AbbVie has filed for approval of a regimen based on its Venclexta therapy for previously untreated patients with chronic lymphocytic leukaemia (CLL), in combination with an AstraZeneca drug. The ...
Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Amy is an ACA and the CEO and founder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback